AU2004286322A1 - Novel multipotent stem cells and use thereof - Google Patents
Novel multipotent stem cells and use thereof Download PDFInfo
- Publication number
- AU2004286322A1 AU2004286322A1 AU2004286322A AU2004286322A AU2004286322A1 AU 2004286322 A1 AU2004286322 A1 AU 2004286322A1 AU 2004286322 A AU2004286322 A AU 2004286322A AU 2004286322 A AU2004286322 A AU 2004286322A AU 2004286322 A1 AU2004286322 A1 AU 2004286322A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- bone marrow
- cell
- hbmsc
- graft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002894 multi-fate stem cell Anatomy 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims description 284
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 99
- 210000002889 endothelial cell Anatomy 0.000 claims description 76
- 210000001185 bone marrow Anatomy 0.000 claims description 74
- 230000004069 differentiation Effects 0.000 claims description 74
- 210000000130 stem cell Anatomy 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- 210000001519 tissue Anatomy 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 32
- 210000002798 bone marrow cell Anatomy 0.000 claims description 30
- -1 Oct 4 Proteins 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 27
- 206010061216 Infarction Diseases 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 25
- 230000001737 promoting effect Effects 0.000 claims description 22
- 230000007574 infarction Effects 0.000 claims description 21
- 210000002569 neuron Anatomy 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 18
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 16
- 230000001537 neural effect Effects 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 15
- 206010019280 Heart failures Diseases 0.000 claims description 14
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 14
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 14
- 101150114527 Nkx2-5 gene Proteins 0.000 claims description 14
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 14
- 230000001464 adherent effect Effects 0.000 claims description 13
- 230000004217 heart function Effects 0.000 claims description 13
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 12
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 claims description 12
- 230000007910 cell fusion Effects 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 230000003511 endothelial effect Effects 0.000 claims description 12
- 230000033001 locomotion Effects 0.000 claims description 12
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 11
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 11
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 11
- 230000002491 angiogenic effect Effects 0.000 claims description 11
- 208000031225 myocardial ischemia Diseases 0.000 claims description 11
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 10
- 102100040120 Prominin-1 Human genes 0.000 claims description 10
- 208000019622 heart disease Diseases 0.000 claims description 10
- 101710150336 Protein Rex Proteins 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 9
- 239000003636 conditioned culture medium Substances 0.000 claims description 9
- 210000004748 cultured cell Anatomy 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 8
- 108091035539 telomere Proteins 0.000 claims description 8
- 102000055501 telomere Human genes 0.000 claims description 8
- 210000003411 telomere Anatomy 0.000 claims description 8
- 208000020446 Cardiac disease Diseases 0.000 claims description 7
- 102000043129 MHC class I family Human genes 0.000 claims description 7
- 108091054437 MHC class I family Proteins 0.000 claims description 7
- 102000043131 MHC class II family Human genes 0.000 claims description 7
- 108091054438 MHC class II family Proteins 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 claims description 6
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102100037241 Endoglin Human genes 0.000 claims description 5
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 5
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000002771 cell marker Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000002592 echocardiography Methods 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 230000002861 ventricular Effects 0.000 claims description 5
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 230000035488 systolic blood pressure Effects 0.000 claims description 4
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 3
- 102100035487 Nectin-3 Human genes 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000004904 shortening Methods 0.000 claims description 3
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 2
- 150000004648 butanoic acid derivatives Chemical class 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims 4
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims 4
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims 4
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 3
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 claims 1
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 55
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 30
- 210000002216 heart Anatomy 0.000 description 30
- 210000004165 myocardium Anatomy 0.000 description 27
- 230000002107 myocardial effect Effects 0.000 description 24
- 208000010125 myocardial infarction Diseases 0.000 description 23
- 238000002054 transplantation Methods 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000004927 fusion Effects 0.000 description 20
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 18
- 238000003501 co-culture Methods 0.000 description 18
- 230000000747 cardiac effect Effects 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 239000003226 mitogen Substances 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 210000001736 capillary Anatomy 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 210000005240 left ventricle Anatomy 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 8
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 8
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 102000008790 VE-cadherin Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 108010018828 cadherin 5 Proteins 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 102100022464 5'-nucleotidase Human genes 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 6
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 6
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 210000002304 esc Anatomy 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010063503 Actinin Proteins 0.000 description 5
- 102000010825 Actinin Human genes 0.000 description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 5
- 210000004504 adult stem cell Anatomy 0.000 description 5
- 230000001625 cardiomyogenic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 210000005003 heart tissue Anatomy 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 230000003076 paracrine Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 4
- 102100025304 Integrin beta-1 Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 101150055123 afp gene Proteins 0.000 description 4
- 210000000648 angioblast Anatomy 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000002403 aortic endothelial cell Anatomy 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 210000003995 blood forming stem cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000004248 oligodendroglia Anatomy 0.000 description 4
- 230000022379 skeletal muscle tissue development Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 3
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 3
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 3
- 101150104791 MYOC gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 102000006783 calponin Human genes 0.000 description 3
- 108010086826 calponin Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 101150022753 galc gene Proteins 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000046949 human MSC Human genes 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 102100034594 Angiopoietin-1 Human genes 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 208000037891 myocardial injury Diseases 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000001020 neural plate Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 241000533845 Enterolobium cyclocarpum Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000611892 Homo sapiens Platelet-derived growth factor D Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 108700028031 Myelin Basic Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100040682 Platelet-derived growth factor D Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 108010041865 Ulex europaeus lectins Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010051583 Ventricular Myosins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 108010022164 acetyl-LDL Proteins 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000000252 angiomatosis Diseases 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- 108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 230000004398 heart morphogenesis Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003209 hepatic oval cell Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 108010091047 neurofilament protein H Proteins 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000006488 postnatal vasculogenesis Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108700038606 rat Smooth muscle Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51532003P | 2003-10-28 | 2003-10-28 | |
| US60/515,320 | 2003-10-28 | ||
| PCT/US2004/036298 WO2005042723A2 (fr) | 2003-10-28 | 2004-10-28 | Nouvelles cellules souches multipotentes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004286322A1 true AU2004286322A1 (en) | 2005-05-12 |
Family
ID=34549391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004286322A Abandoned AU2004286322A1 (en) | 2003-10-28 | 2004-10-28 | Novel multipotent stem cells and use thereof |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1685237A4 (fr) |
| JP (1) | JP2007519397A (fr) |
| KR (1) | KR20070007030A (fr) |
| CN (1) | CN101072867A (fr) |
| AU (1) | AU2004286322A1 (fr) |
| CA (1) | CA2543794A1 (fr) |
| WO (1) | WO2005042723A2 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007047963A2 (fr) * | 2005-10-20 | 2007-04-26 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Utilisation de cellules souches derivees de la moelle osseuse dans le traitement de l'ischemie |
| CN101573441A (zh) * | 2005-12-08 | 2009-11-04 | 路易斯维尔大学研究基金会有限公司 | 非常小的胚胎样（vsel）干细胞及分离和利用其的方法 |
| US9155762B2 (en) | 2005-12-08 | 2015-10-13 | University Of Louisville Research Foundation, Inc. | Uses and isolation of stem cells from bone marrow |
| AU2007243221A1 (en) * | 2006-04-28 | 2007-11-08 | Tulane University Health Sciences Center | Methods for treating diabetes |
| US20100260725A1 (en) * | 2007-09-24 | 2010-10-14 | Mohapatra Shyam S | Materials and Methods for Treating Allergic and Inflammatory Conditions |
| WO2011053690A1 (fr) * | 2009-10-30 | 2011-05-05 | The University Of North Carolina At Chapel Hill | Cellules souches pluripotentes à partir de l'arbre biliaire extrahépatique et procédés pour leur isolement |
| US11312940B2 (en) | 2015-08-31 | 2022-04-26 | University Of Louisville Research Foundation, Inc. | Progenitor cells and methods for preparing and using the same |
| US11072777B2 (en) | 2016-03-04 | 2021-07-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) |
| CN115369077B (zh) * | 2022-07-29 | 2023-07-18 | 佛山市中科律动生物科技有限公司 | Meflc细胞株及其构建方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8401498A (en) * | 1997-07-14 | 1999-02-10 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
| US6291240B1 (en) * | 1998-01-29 | 2001-09-18 | Advanced Tissue Sciences, Inc. | Cells or tissues with increased protein factors and methods of making and using same |
| US6328762B1 (en) * | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
-
2004
- 2004-10-28 WO PCT/US2004/036298 patent/WO2005042723A2/fr active Application Filing
- 2004-10-28 EP EP04796882A patent/EP1685237A4/fr not_active Withdrawn
- 2004-10-28 AU AU2004286322A patent/AU2004286322A1/en not_active Abandoned
- 2004-10-28 JP JP2006538403A patent/JP2007519397A/ja active Pending
- 2004-10-28 CN CNA2004800391847A patent/CN101072867A/zh active Pending
- 2004-10-28 CA CA002543794A patent/CA2543794A1/fr not_active Abandoned
- 2004-10-28 KR KR1020067010523A patent/KR20070007030A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005042723A9 (fr) | 2005-08-18 |
| EP1685237A2 (fr) | 2006-08-02 |
| WO2005042723A2 (fr) | 2005-05-12 |
| CN101072867A (zh) | 2007-11-14 |
| JP2007519397A (ja) | 2007-07-19 |
| KR20070007030A (ko) | 2007-01-12 |
| WO2005042723A3 (fr) | 2007-03-29 |
| EP1685237A4 (fr) | 2007-12-26 |
| CA2543794A1 (fr) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoon et al. | Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction | |
| Poulsom et al. | Adult stem cell plasticity | |
| Leor et al. | Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium? | |
| JP5292106B2 (ja) | 損傷心筋の修復および／または再生の方法および組成物 | |
| Smits et al. | The role of stem cells in cardiac regeneration | |
| US20090155225A1 (en) | Uses and isolation of very small of embryonic-like (vsel) stem cells | |
| US20120021482A1 (en) | Methods for isolating very small embryonic-like (vsel) stem cells | |
| US8747905B2 (en) | Therapeutic use of CD31 expressing cells | |
| US9155762B2 (en) | Uses and isolation of stem cells from bone marrow | |
| KR20110034617A (ko) | 심장 조직을 처치하는 세포를 이용하는 조성물 및 방법 | |
| US20070253937A1 (en) | Novel multipotent stem cells and use thereof | |
| Soejitno et al. | Clinical applications of stem cell therapy for regenerating the heart | |
| AU2004286322A1 (en) | Novel multipotent stem cells and use thereof | |
| WO2002075302A1 (fr) | Methode de traitement therapeutique d'une forme cliniquement identifiee de cardiopathie chez un mammifere vivant | |
| US20090155220A1 (en) | Use of Bone-Marrow Derived Stem Cells to Treat Ischemia | |
| US20040071665A1 (en) | Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal | |
| Shibuya et al. | Tongue muscle-derived stem cells express connexin 43 and improve cardiac remodeling and survival after myocardial infarction in mice | |
| Emanueli et al. | In search of the best candidate for regeneration of ischemic tissues | |
| Poole | Cardiovascular therapeutics derived from the paracrine biology of adult human progenitor cells | |
| Gnecchi et al. | Adult Stem Cell-Based Therapy for the Heart | |
| Iwasaki et al. | Cardiomyogenesis for Functional Regenerative Recovery After Myocardial Infarction | |
| Al-Kindi et al. | Cellular cardiomyoplasty: evidence of cellular therapy, mechanisms and controversies | |
| WO2007038933A2 (fr) | Methode de production de cellules greffables dans le coeur | |
| Chen | The role of human blood-vessel-derived stem cells in tissue repair and regeneration | |
| Zeng | Swine bone marrow-derived multipotent adult stem cells and its application in swine hearts with postinfarction LV dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK3 | Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination |